The medication handles appetite and the B6 handles nausea, but everything else, protein intake, hydration, movement, sleep, and stress management, determines how much benefit you actually extract from the treatment
In phase 3 clinical trials, patients lost an average of 15 more pounds with tirzepatide than with a placebo and an average of 23 pounds more than the placebo group when they used tirzepatide and insulin
Quick Answer: GLP-1 agonists are not currently approved or recommended for treating alcohol use disorder in the UK, though early research suggests potential effects on alcohol consumption via brain reward pathways
Enjoy the benefits of advanced, minimally invasive technology
In contrast, Semaglutide GLP-1, which is administered weekly, may initially appear more expensive